argenx to Present at J.P. Morgan Healthcare Conference
Ticker: ARGX · Form: 6-K · Filed: Jan 13, 2025 · CIK: 1697862
Sentiment: neutral
Topics: conference-participation, investor-update
TL;DR
argenx speaking at JPM Healthcare Conf Jan 15th, tune in!
AI Summary
On January 13, 2025, argenx SE announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company will present on January 15, 2025, at 11:30 AM EST, providing an update on its business and pipeline. This presentation will be accessible via a webcast on the investor relations section of the argenx website.
Why It Matters
This presentation offers investors and the public a chance to hear directly from argenx management about their strategic direction and progress in the biotechnology sector.
Risk Assessment
Risk Level: low — This filing is a routine announcement of participation in a conference, not a material event or financial disclosure.
Key Players & Entities
- argenx SE (company) — Registrant
- J.P. Morgan Healthcare Conference (company) — Event
- January 15, 2025 (date) — Presentation Date
- 11:30 AM EST (time) — Presentation Time
FAQ
What is the specific date and time of argenx's presentation at the J.P. Morgan Healthcare Conference?
argenx is scheduled to present on January 15, 2025, at 11:30 AM EST.
Where can investors access the webcast of the presentation?
The webcast will be available on the investor relations section of the argenx website.
What is the name of the conference argenx is participating in?
argenx is participating in the 43rd Annual J.P. Morgan Healthcare Conference.
What type of information will argenx provide during its presentation?
argenx will provide a business and pipeline update.
What is the filing type and date?
This is a Form 6-K filed on January 13, 2025.
Filing Stats: 306 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-01-13 06:10:36
Filing Documents
- tm253121d1_6k.htm (6-K) — 12KB
- tm253121d1_ex99-1.htm (EX-99.1) — 42KB
- tm253121d1_ex99-2.htm (EX-99.2) — 38KB
- tm253121d1_ex99-2img001.jpg (GRAPHIC) — 151KB
- tm253121d1_ex99-2img002.jpg (GRAPHIC) — 330KB
- tm253121d1_ex99-2img003.jpg (GRAPHIC) — 187KB
- tm253121d1_ex99-2img004.jpg (GRAPHIC) — 206KB
- tm253121d1_ex99-2img005.jpg (GRAPHIC) — 177KB
- tm253121d1_ex99-2img006.jpg (GRAPHIC) — 179KB
- tm253121d1_ex99-2img007.jpg (GRAPHIC) — 150KB
- tm253121d1_ex99-2img008.jpg (GRAPHIC) — 126KB
- tm253121d1_ex99-2img009.jpg (GRAPHIC) — 147KB
- tm253121d1_ex99-2img010.jpg (GRAPHIC) — 114KB
- tm253121d1_ex99-2img011.jpg (GRAPHIC) — 115KB
- tm253121d1_ex99-2img012.jpg (GRAPHIC) — 155KB
- tm253121d1_ex99-2img013.jpg (GRAPHIC) — 129KB
- tm253121d1_ex99-2img014.jpg (GRAPHIC) — 139KB
- tm253121d1_ex99-2img015.jpg (GRAPHIC) — 147KB
- tm253121d1_ex99-2img016.jpg (GRAPHIC) — 174KB
- tm253121d1_ex99-2img017.jpg (GRAPHIC) — 147KB
- tm253121d1_ex99-2img018.jpg (GRAPHIC) — 126KB
- tm253121d1_ex99-2img019.jpg (GRAPHIC) — 174KB
- tm253121d1_ex99-2img020.jpg (GRAPHIC) — 145KB
- tm253121d1_ex99-2img021.jpg (GRAPHIC) — 114KB
- tm253121d1_ex99-2img022.jpg (GRAPHIC) — 142KB
- tm253121d1_ex99-2img023.jpg (GRAPHIC) — 133KB
- tm253121d1_ex99-2img024.jpg (GRAPHIC) — 109KB
- tm253121d1_ex99-2img025.jpg (GRAPHIC) — 132KB
- tm253121d1_ex99-2img026.jpg (GRAPHIC) — 133KB
- tm253121d1_ex99-2img027.jpg (GRAPHIC) — 114KB
- tm253121d1_ex99-2img028.jpg (GRAPHIC) — 196KB
- tm253121d1_ex99-2img029.jpg (GRAPHIC) — 154KB
- tm253121d1_ex99-2img030.jpg (GRAPHIC) — 162KB
- 0001104659-25-002791.txt ( ) — 6440KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: January 13, 2025 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel